Treatment options for relapsed/refractory systemic light-chain (AL) amyloidosis: current perspectives

S Sarosiek, V Sanchorawala - Journal of Blood Medicine, 2019 - Taylor & Francis
Systemic immunoglobulin light chain (AL) amyloidosis is a disorder characterized by the
production of clonal serum free light chains that misfold, aggregate, and deposit in vital …

Fibril-directed therapies in systemic light chain AL amyloidosis

D Bhutani, S Leng, S Lentzsch - Clinical Lymphoma Myeloma and …, 2019 - Elsevier
Immunoglobulin light chain amyloidosis (AL amyloidosis) is a plasma cell disorder leading
to the production and extracellular deposition of abnormal immunoglobulin light chains …

Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside

M Basset, M Nuvolone, G Palladini… - Expert Review of …, 2020 - Taylor & Francis
Introduction Immunoglobulin light chain (AL) amyloidosis is one of the most frequent
systemic amyloidosis in Western countries. It is caused by a B-cell clone producing a …

Systemic Light Chain Amyloidosis

V Sanchorawala - New England Journal of Medicine, 2024 - Mass Medical Soc
Key Points Systemic Light Chain Amyloidosis Immunoglobulin light chain (AL) amyloidosis
is a rare disease that occurs when a plasma cell disorder produces monoclonal light chains …

Peripheral nervous, hepatic, and gastrointestinal endpoints for AL amyloidosis clinical trials: report from the amyloidosis forum multi-organ system working group

ML Mauermann, JO Clarke, WJ Litchy, L Obici… - Advances in …, 2023 - Springer
Systemic immunoglobulin light chain (AL) amyloidosis is a heterogeneous rare disease
driven by a destructive monoclonal gammopathy and typified by misfolded immunoglobulin …

Nonchemotherapy treatment of immunoglobulin light chain amyloidosis

L Van Doren, S Lentzsch - Acta Haematologica, 2020 - karger.com
Immunoglobulin light chain amyloidosis (AL amyloidosis) is a rare, life-threatening disease
characterized by the deposition of misfolded proteins in vital organs such as the heart, the …

Future directions in the clinical management of amyloid light-chain amyloidosis

S Haider, N Ahmad, E Anaissie… - Leukemia & lymphoma, 2014 - Taylor & Francis
Amyloid light-chain (AL) amyloidosis results from extracellular deposition of fibril-forming
monoclonal immunoglobulin light chains (LCs) usually secreted by a plasma cell (PC) clone …

[HTML][HTML] Current updates on the management of AL amyloidosis

M Elsayed, S Usher, MH Habib, N Ahmed… - Journal of …, 2021 - ncbi.nlm.nih.gov
Systemic immunoglobulin light chain (AL) amyloidosis is a rare but fatal disease. It results
from clonal proliferation of plasma cells with excessive production of insoluble misfolded …

[HTML][HTML] Recent advances in understanding and treating immunoglobulin light chain amyloidosis

T Badar, A D'Souza, P Hari - F1000Research, 2018 - ncbi.nlm.nih.gov
Immunoglobulin (Ig) light chain (AL) amyloidosis is a clonal plasma cell disorder
characterized by misfolded Ig light chain deposition in vital organs of the body, resulting in …

Diagnosis and management of systemic light chain AL amyloidosis

D Bhutani, S Lentzsch - Pharmacology & Therapeutics, 2020 - Elsevier
AL amyloidosis is a plasma cell disorder leading to the production and extracellular
deposition of abnormal immunoglobulin light chains called amyloid. The pathogenesis of the …